Avadel Pharmaceuticals (AVDL) Cash from Operations (2016 - 2022)
Historic Cash from Operations for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Q4 2022 value amounting to -$15.4 million.
- Avadel Pharmaceuticals' Cash from Operations rose 3172.49% to -$15.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$70.3 million, marking a year-over-year increase of 906.22%. This contributed to the annual value of -$46.9 million for FY2024, which is 6349.96% up from last year.
- Avadel Pharmaceuticals' Cash from Operations amounted to -$15.4 million in Q4 2022, which was up 3172.49% from -$6.8 million recorded in Q3 2022.
- In the past 5 years, Avadel Pharmaceuticals' Cash from Operations registered a high of -$1.4 million during Q2 2019, and its lowest value of -$34.0 million during Q1 2022.
- In the last 5 years, Avadel Pharmaceuticals' Cash from Operations had a median value of -$16.7 million in 2018 and averaged -$15.9 million.
- As far as peak fluctuations go, Avadel Pharmaceuticals' Cash from Operations crashed by 56213.21% in 2018, and later soared by 9274.1% in 2019.
- Quarter analysis of 5 years shows Avadel Pharmaceuticals' Cash from Operations stood at -$24.5 million in 2018, then surged by 66.35% to -$8.3 million in 2019, then plummeted by 131.73% to -$19.1 million in 2020, then fell by 17.68% to -$22.5 million in 2021, then surged by 31.72% to -$15.4 million in 2022.
- Its Cash from Operations was -$15.4 million in Q4 2022, compared to -$6.8 million in Q3 2022 and -$14.1 million in Q2 2022.